FOR MENTAL HEALTH: Mental Health Declaration of Human Rights

Citizens Commission on Human Rights

Many who struggled during the pandemic may look for help to return to a "normal life". Knowing one's mental health human rights is an important first step.

WASHINGTON, DC, US, May 31, 2021 /EINPresswire.com/ — The Mental Health Declaration of Human Rights, like the UN Universal Declaration of Human Rights that preceded it, is so fundamental and basic that it should be known broadly by the general public, yet many still do not know their rights. One group is working to change that.

All human rights organizations set forth codes by which they align their purposes and activities. The Mental Health Declaration of Human Rights articulates the guiding principles and goals of Citizens Commission on Human Rights (CCHR).

In 2017, Dr. Dainius Pūras, the United Nations Special Rapporteur on the right to health, called for a revolution in mental health care around the world to “end decades of neglect, abuse and violence,” stating, “There is now unequivocal evidence of the failures of a system that relies too heavily on the biomedical model of mental health services, including the front-line and excessive use of psychotropic medicines, and yet these models persist.”

Human rights include the right to one’s own mind, and to protect oneself and one’s loved ones against any abusive or harmful “treatments” given under the guise of mental health.

Every man, woman and child is entitled to the fundamental human rights set forth in this Mental Health Declaration of Human Rights, regardless of race, political ideology, religious, cultural or social beliefs.

Given the fact that virtually no human or civil rights adequately protect citizens from mental health abuses, it is vital that the following rights be recognized and that all countries adopt this Declaration.

THE MENTAL HEALTH DECLARATION OF HUMAN RIGHTS

A. The right to full informed consent, including:

1. The scientific/medical test confirming any alleged diagnoses of psychiatric disorder and the right to refute any psychiatric diagnoses of mental “illness” that cannot be medically confirmed.

2. Full disclosure of all documented risks of any proposed drug or mental “treatment.”

3. The right to be informed of all available medical treatments which do not involve the administration of a psychiatric drug or treatment.

4. The right to refuse psychiatric drugs documented by international drug regulatory agencies to be harmful and potentially lethal.

5. The right to refuse to undergo electroshock or psycho-surgery.

B. No person shall be forced to undergo any psychiatric or psychological treatment against his or her will.

C. No person, man, woman or child, may be denied his or her personal liberty by reason of mental illness, without a fair jury trial by laymen and with proper legal representation.

D. No person shall be admitted to or held in a psychiatric institution, hospital or facility because of their political, religious or cultural or social beliefs and practices.

E. Any patient has:

1. The right to be treated with dignity as a human being.

2. The right to hospital amenities without distinction as to race, color, sex, language, religion, political opinion, social origin or status by right of birth or property.

3. The right to have a thorough, physical and clinical examination by a competent registered general practitioner of one’s choice, to ensure that one’s mental condition is not caused by any undetected and untreated physical illness, injury or defect, and the right to seek a second medical opinion of one’s choice.

4. The right to fully equipped medical facilities and appropriately trained medical staff in hospitals, so that competent physical, clinical examinations can be performed.

5. The right to choose the kind or type of therapy to be employed, and the right to discuss this with a general practitioner, healer or minister of one’s choice.

6. The right to have all the side effects of any offered treatment made clear and understandable to the patient, in written form and in the patient’s native language.

7. The right to accept or refuse treatment but in particular, the right to refuse sterilization, electroshock treatment, insulin shock, lobotomy (or any other psychosurgical brain operation), aversion therapy, narcotherapy, deep sleep therapy and any drugs producing unwanted side effects.

8. The right to make official complaints, without reprisal, to an independent board which is composed of non-psychiatric personnel, lawyers and lay people. Complaints may encompass any torturous, cruel, inhuman or degrading treatment or punishment received while under psychiatric care.
9. The right to have private counsel with a legal advisor and to take legal action.

10. The right to discharge oneself at any time and to be discharged without restriction, having committed no offense.

11. The right to manage one’s own property and affairs with a legal advisor, if necessary, or if deemed incompetent by a court of law, to have a State appointed executor to manage such until one is adjudicated competent. Such executor is accountable to the patient’s next of kin, or legal advisor or guardian.

12. The right to see and possess one’s hospital records and to take legal action with regard to any false information contained therein which may be damaging to one’s reputation.

13. The right to take criminal action, with the full assistance of law enforcement agents, against any psychiatrist, psychologist or hospital staff for any abuse, false imprisonment, assault from treatment, sexual abuse or rape, or any violation of mental health or other law. And the right to a mental health law that does not indemnify or modify the penalties for criminal, abusive or negligent treatment of patients committed by any psychiatrist, psychologist or hospital staff.

14. The right to sue psychiatrists, their associations and colleges, the institution, or staff for unlawful detention, false reports, or damaging treatment.

15. The right to work or to refuse to work, and the right to receive just compensation on a pay-scale comparable to union or state/national wages for similar work, for any work performed while hospitalized.

16. The right to education or training so as to enable one better to earn a living when discharged, the right of choice over what kind of education or training is received.

17. The right to receive visitors and a minister of one’s own faith.

18. The right to make and receive telephone calls and the right to privacy with regard to all personal correspondence to and from anyone.

19. The right to freely associate or not with any group or person in a psychiatric institution, hospital or facility.

20. The right to a safe environment without having in the environment, persons placed there for criminal reasons.

21. The right to be with others of one’s own age group.

22. The right to wear personal clothing, to have personal effects and to have a secure place in which to keep them.

23. The right to daily physical exercise in the open.

24. The right to a proper diet and nutrition and to three meals a day.

25. The right to hygienic conditions and non-overcrowded facilities, and to sufficient, undisturbed leisure and rest.

Reprinted from the Citizens Commission on Human Rights Colorado website, www.cchrcolorado.org

The Citizens Commission on Human Rights National Office in Washington, DC, has advocated for mental health rights at the state and federal level. The CCHR traveling exhibit has been displayed in Washington, DC, at the Congressional Black Caucus Foundation Annual Legislative Caucus, as well as other locations. The exhibit has toured more than 441 major cities around the world and has educated over 800,000 people on the history and contemporary practices of psychiatry which are still rampant with abuse.

About Citizens Commission on Human Rights: CCHR is a nonprofit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enacted patient and consumer protections. CCHR was co-founded in 1969 by the Church of Scientology and Professor of Psychiatry Emeritus Dr. Thomas Szasz.

Media Relations
Citizens Commission on Human Rights, National Office
+1 202-349-9267
email us here

CCHR What We Believe


Source: EIN Presswire

Sayed Sayedy describes Training, coaching and mediation as an independent approach for individual problem solving

Photo of Sayed Sayedy

Photo of Sayed Sayedy

Photo of Sayed Sayedy

What is training? What is coaching? What is mediation?

MüNCHEN, BAYERN, DEUTSCHLAND, May 31, 2021 /EINPresswire.com/ — What is training?
The term training is probably the term most frequently encountered in a sporting context. There it means „training” or „trying out“ with the aim of improving oneself. Here it has a very similar meaning. It is a question of training and the transfer of knowledge. In contrast to coaching, in training tips and clarifications are permitted; they are valuable and target-oriented. „The aim is for me to pass on to you knowledge and competences that I have acquired as a trainer“, makes the point Mr. Sayed Sayedy.

What is coaching?
Coaching does not involve giving you advice and explaining to you how you can best shape your life, because you yourself can best decide what is right for you. But everybody can find themselves in situations they are not happy with. And it can often be very hard to find a way out by oneself. „My task as a coach is therefore to support you actively in such situations and in your search for the right solutions“, thus, Mr. Sayed Sayedy emphasized in his role as a Life Coach. To this purpose he works with systematics and methods individually tailored to your needs. It is most emphatically not his task as a coach to give my clients advice or even guidance; rather he is happy to support them so that they can feel contented in themselves, to trust in their own strength and to experience more connectivity and appreciation.“ Mr. Sayed Sayedy wants them to feel fulfilled and happy in the present, so that they can look gratefully back to the past and confidently forward into the future. That is his goal in coaching.

What is mediation?
With the help of mediation a conflict can be dealt with very specifically. „In contrast to coaching, where I can search for solution options with only one person involved in the conflict, in mediation it is important that all the parties to the conflict take part in the process”, this is the perspective of Mr. Sayed Sayedy as a mediator. As a mediator he plays a neutral role here. This means that he do not decide which party is in the right, but accompany them on the path to solutions to which all parties can say „yes“.

Bio of Sayed Sayedy: Born in Parwan, Afghanistan, in 1992, he studied sociology and social work in Parwan. While at school and university he worked as a helper and activist for the empowerment of young persons and worked as a trainer at the Institute for International Cooperation of the German Adult Education Association (Deutscher Volkshochschul-Verband) until 2013. From 2001 to 2014 he worked as a translator and intercultural facilitator for the international NATO security force ISAF, where he also trained as an IT specialist.

Together with his mother he campaigned for human rights and especially for women‘s rights. This is why he had to leave his homeland and came to Munich at the start of 2015. During this time, too, he was active as a cultural facilitator to minimize difficulties and misunderstandings.

He is currently studying „Training and Development” at the University of Salzburg and is working as a freelance trainer and communications coach in the intercultural field. He is working full-time for the project „HEROES – Against Suppresion in the Name of Honour“ in Munich and in a voluntary capacity as a migration and integration counselor. He assists refugees in asylum matters or with integration on the job market. He is also active for „KINO ASYL“, „UNSER.FILM“, and supports educational and civilian peace projects in Afghanistan and Cambodia.

Sayed Sayedy
www.sayedy.com
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Non Profit Launches Business Pandemic Preparedness System

Press Conference June 1st, 2021, 11:00 am EST; the world needs pandemic preparedness, sustainability, and universal safe business practices.

We have to change the narrative. We need to take the politics out of our governance. We need to come together as a community if we are to be successful.”

— Steve Anderson

TORONTO, ONTARIO, CANADA, May 31, 2021 /EINPresswire.com/ — Over the past year, SmALL businesses have felt helpless, hopeless, unsupported, and confused. Witnessing the pain and challenges felt and faced by honest, hardworking people in our communities, it became very clear we MUST take action. This sparked the inception of the organization called Social Distance Management (SDM).

Edward Henry Company (EHCO) has made the decision to give away all licensing rights and intellectual property of SDM, which includes Social Distance Advisory (SDA), Social Distance Compliance (SDC) systems, and research to SmALL Business is Essential (SBE).

SDM believes that all businesses need universal compliance measures to operate safely during a pandemic and other unprecedented times. By having access to these practical systems, SBE will have the resources it needs to develop the support for all businesses. ALL businesses are essential, and business continuity is the focus. Any opportunities managed from these systems will help all businesses secure and implement adequate steps to stay open, thrive, and have their voices heard.

The Journey of Social Distance Management

In March of 2020, EHCO started SDM with a mission to stand by businesses. Two months later, on May 11, 2020, with extensive research, collaboration and data collection, they released their first version of universal compliance standards.

Under SDM, sub-resources, including SDA and SDC systems, were established to display universal compliance guidelines and assess the threat levels in specific areas to protect the population. The idea to start SDM came from the utmost care about people and businesses, not from a political approach. Universal health measures and the life of our economy are not two isolated conversations. It is ONE conversation.

To contribute to the information gathered, in July of 2020, a Research Internship was formed to discover and outline details on various businesses in Canada and the United States. The outcome of the research included details which contributed to SDC, such as further development of safety protocols, requirements for operation, compliance measures, capacity limits, and PPE requirements. SDM used the data collection to create additional tools, such as self-assessment audits that provide a checklist for what businesses need to stay compliant and operate safely.

Taking its cue from other systems such as ISO, Homeland Security, The World Health Organization, and research from John Hopkins University, SDM developed its Advisory system. This system was developed with the intent to assist businesses and communities in preparing for crises and mitigating restrictions. “There needs to be accountability to the decisions that are being made that affect our small businesses,” said President of EHCO, Edward Henry.

The Advisory system narrows in on the WHO’s Pandemic Phases and the Homeland Security system and uses five levels of risk and threat: low, moderate, substantial, severe, and critical. The colors associated include green, blue, yellow, orange, and red. Each phase clearly defines which business practices, products, and services are considered essential and non-essential and the types of businesses permitted to open during each phase. The Advisory system is currently in the process of implementing data from John Hopkins University, along with data collected by other reputable models.

Despite the aforementioned systems, resources, and extensive research to support our findings, ambiguous guidelines still remain. Therefore, businesses are left without genuine reasons as to why they cannot safely reopen and recover.

A Multi-faceted Problem Requires Innovative Solutions

Stand By SmALL Businesses and Our Communities

SmALL Business is Essential

After spending some time in the development phase, SDM ventured out and sought support from government officials and local politicians. After COUNTLESS meetings and constantly being redirected elsewhere, it was time to take drastic action. Edward Henry states, “Limited power is not an excuse for not doing the right thing.” This year has been about a lot of the wrong things, and in the beginning, SDM was seen as a profit-making opportunity, and taking advantage of a terrible situation. The lack of change cannot continue. Coming together as a collective unit is essential.

For sustainable change to happen, SDM’s resources need to be placed in the right hands. They need to be placed with an organization that isn’t narrow minded, but bilateral with its thinking so sectors, such as health and business can come together. SBE is a not-for-profit association that operates based on three core pillars: pandemic preparedness, sustainability, and safe business practices. SBE aims to collectively arm small businesses with the support, protection, and resources needed to operate safely while envisioning economic recovery and stability through business unity.

This pandemic is not just a small business problem; it’s a world problem. The government’s attempt to segregate businesses into non-essential and essential classifications created ambiguity. This ambiguity initiated the thought that, not some, but ALL businesses are essential. As EHCO releases all of its SDM systems, traffic, assessment, and auditing models to SBE, a new leadership position begins. SBE’s goals encompass the severity of the issue at hand, which is why there is no better person for the job than Steve Anderson. As a Social Entrepreneur, Olympic Gold Medal Coach, and Community Champion, Anderson takes over as President of the not-for-profit association SBE. Edward Henry states, “My choice to recruit Steve Anderson was because of his character, coaching background, competitive nature to overcome challenges, and his experience with a multi-faceted range of individuals.” Speaking to Anderson’s character, he doesn’t make excuses. Steve is a good man, and SBE needs his character to bring everyone together.

Along with Anderson’s motivating character, he is the first African American to coach an Olympic team in indoor or beach volleyball and the first to win an Olympic Gold Medal in either practice. Anderson is highly committed to being the driving force behind SBE to support ALL businesses. He, along with the efforts of SBE, will pave the way towards a better normal.

Our current actions reflect our future results. If we don’t continue putting in effort and showing our care for our businesses, we will continue losing pieces of our community and, in turn, our economy. Small businesses have experienced unfair measures and restrictions, putting them at risk for permanent closure. Continuous lockdowns are not a solution. “This current pandemic has cost over $20 trillion because we were not prepared,” said Edward Henry. The definition of insanity is to perform the same actions and expect different results. “We will do this over again if we don’t start changing the way we do things,” he added. The focus needs to be on Social Distance Compliance and universal protocols to preserve business continuity. If we want an improved normal, we need to stand by SmALL businesses and our communities. There is no better time than now to help businesses transition from lockdowns and longer than expected restrictions.

Register for Zoom Press Conference
https://zoom.us/meeting/register/tJEsde2rrjorHNwu-EbLrWmGCD9RyAUk9WEb

Location 10 Sunray Street, Suite 23
Whitby, Ontario L1N 9B5
Limited Space for TV Media only, call contacts below to confirm or email info@edwardhenry.com

Edward Henry
Edward Henry Company
+1 647-725-7575
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Global Humic Based Biostimulants Market Trends, Strategies, & Opportunities In The Humic Based Biostimulants Market 2021

Humic Based Biostimulants Market Report 2021: COVID-19 Growth And Change

Humic Based Biostimulants Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Humic Based Biostimulants Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, May 31, 2021 /EINPresswire.com/ — According to the new market research report ‘Humic Based Biostimulants Humic Based Biostimulants Global Market Report 2021: COVID-19 Growth And Change’ published by The Business Research Company, the global humic-based biostimulants market is expected to grow from $496.46 million in 2020 to $538.61 million in 2021 at a compound annual growth rate (CAGR) of 8.49%. The growth is mainly due to the benefits associated with humic based biostimulants, rising need of sustainable agriculture and reduced in exploitation and wastage of conventional synthetic fertilizers. The humic-based biostimulants market is expected to reach $807.64 million in 2025 at a CAGR of 10.4%. Increase in the demand for the adoption of sustainable solutions in farming is driving the market growth of humic-based biostimulants.

Request For A Sample For The Global Humic Based Biostimulants Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4094&type=smp

The humic-based biostimulants market consists of sales humic-based biostimulants and related services by entities (organizations, sole traders and partnerships) that provide humic-based biostimulants. Biostimulants are substances applied to plants to enhance nutrition efficiency, abiotic stress tolerance and increase crop quality traits. Humic based biostimulants are commonly used in horticulture.

Trends In The Global Humic Based Biostimulants Market
Innovations in humic-based biosimulants such as chelation with different minerals are shaping the humic-based biostimulants market. Companies across the globe that are working on a wide variety of agricultural solutions with chelated additional minerals to enhance the nutraceutical nature of crops and plants. For instance, HuminTech, a German based humic substances producer, has launched a humic based biostimulant with iron chelation. The product can be used to prevent and correct iron deficiency symptoms in plants, along with increasing the resistance of plants to abiotic stress factors.

Global Humic Based Biostimulants Market Segments:
The global humic based biostimulants market is further segmented based on type and geography.
By Type: Fulvic Acid, Humic Acid, Potassium Humate
By Type Of Formulation: Liquid, Water-Soluble Granules, Water-Soluble Powders
By Mode of Application: Agriculture, Cereals, Fiber Crops, Fruits & Vegetables, Oilseeds
By End-User: Farmers, Related Industries, Research Institutes
By Geography: The global humic based biostimulants market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America is the largest region in the humic-based biosimulants market in 2020.

Read More On The Report For The Global Humic Based Biostimulants Market At:
https://www.thebusinessresearchcompany.com/report/humic-based-biostimulants-global-market-report

Humic Based Biostimulants Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides humic based biostimulants market overviews, analyzes and forecasts market size and growth for the global humic based biostimulants market, humic based biostimulants market share, humic based biostimulants market players, humic based biostimulants market segments and geographies, humic based biostimulants market’s leading competitors’ revenues, profiles and market shares. The humic based biostimulants market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Read Humic Based Biostimulants Global Market Report 2021 from The Business Research Company for information on the following:

Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries

Humic Based Biostimulants Market Organizations Covered: Syngenta Group, Biolchim S.P.A, FMC Corporation, Haifa Group, UPL Limited, Bayer AG, Sikko Industries Ltd

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets. Here is a list of reports from The Business Research Company similar to the Humic Based Biostimulants Global Market Report 2021:

Biostimulants Global Market Report 2021: COVID 19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biostimulants-market-global-report-2020-30-covid-19-growth-and-change

Powder Coatings Global Market Report 2021: COVID 19 Impact And Recovery To 2030
https://www.thebusinessresearchcompany.com/report/powder-coatings-global-market-report

Water Borne Coatings Global Market Report 2021: COVID 19 Impact And Recovery To 2030
https://www.thebusinessresearchcompany.com/report/water-borne-coatings-global-market-report

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

EBRAINS robot simulation one step closer to in-hand object manipulation

Supercomputer at the Swiss National Supercomputing Centre (CSCS) ©CSCS

The physical Shadowhand is one of the world’s most advanced robotic hands. Shadowhand is a Partnering Project of the Human Brain Project © Shadow Robot Company

Rainer Goebel

Mario Senden

A simulation of a robotic hand implemented on the EBRAINS research infrastructure is beginning to perform human-like digit configurations

BRUSSELS, BELGIEN, May 31, 2021 /EINPresswire.com/ — A team of scientists in the Human Brain Project is using the EBRAINS research infrastructure to learn more about how the brain coordinates complex hand movements.

It is easy to take the dexterity of the human hand for granted. Every day we benefit greatly from our ability to manipulate objects with a high degree of control – whether we’re typing on a computer, playing a musical instrument, or even just turning a key to unlock a door.

While these tasks may seem simple, in-hand object manipulation is actually very complex and engages a large-scale brain network encompassing sensory, association, and motor regions.

Now, a team of scientists in the Human Brain Project is implementing this brain network as a biologically constrained recurrent convolutional neural network (RCNN) on EBRAINS. This type of network is often used to model sequence data. The network’s ability to learn sequences of states – for example, how a sequence of limb positions evolves when a certain force is applied to a joint – is especially relevant to robotics.

The design of the RCNN was informed by the EBRAINS Multilevel Human Brain Atlas, which allowed the researchers to identify the connection profile of brain regions involved in complex hand movements. The RCNN was then trained in-silico on supercomputers at the Swiss National Supercomputing Centre, which is part of the EBRAINS high-performance computing infrastructure.

The RCNN was tasked with generating a simple digit configuration – to join fingers with the thumb – which it successfully performed after 2,000 iterations of self-generated experience.

“The RCNN requires hours of simulated experience to train", says Mario Senden, one of the lead scientists. "The EBRAINS high-performance computing infrastructure allows us to speed up the process immensely and train the network in just a few minutes."

The team of scientists is now trying to train the network to perform in-hand object manipulation. “Our aim is to better understand the brain through biologically-inspired functional models and to provide brain-based alternatives to modern engineering solutions”, says Rainer Goebel, one of the head researchers.

Work is also being done to implement the Shadowhand robot – which performed the digit configurations in a simulator – on the EBRAINS Neurorobotics Platform.

“The unique combination of interoperable services on EBRAINS will allow us to break new ground in cognitive computational neuroscience", says Paweł Świeboda, CEO of EBRAINS and Director General of the HBP.

Katrin Amunts, the Scientific Director of the HBP emphasizes: "The workflow shown here incorporates a range of complementary EBRAINS services, including the multilevel human brain atlas, high-performance computing infrastructure, and, eventually, the Neurorobotics Platform. EBRAINS is the only research infrastructure in Europe that offers this powerful combination of services.”

Media Contact:

Peter Zekert
Tel.: +49 2461 61 96860
press@humanbrainproject.eu

Further information:
https://ebrains.eu
https://www.humanbrainproject.eu

ABOUT THE HBP

The Human Brain Project (HBP) is the largest brain science project in Europe and stands among the biggest research projects ever funded by the European Union. At the interface of neuroscience and information technology, the HBP investigates the brain and its diseases with the help of highly advanced methods from computing, neuroinformatics and artificial intelligence, and drives innovation in fields like brain-inspired computing and neurorobotics.

ABOUT EBRAINS

EBRAINS is a new digital research infrastructure, created by the EU-funded Human Brain Project, to foster brain-related research and to help translate the latest scientific discoveries into innovation in medicine and industry, for the benefit of patients and society.
It draws on cutting-edge neuroscience and offers an extensive range of brain data sets, a multilevel brain atlas, modelling and simulation tools, easy access to high-performance computing resources and to robotics and neuromorphic platforms.
All academic researchers have open access to EBRAINS’ state-of-the art services. Industry researchers are also very welcome to use the platform under specific agreements. For more information about EBRAINS, please contact us at info@ebrains.eu or visit www.ebrains.eu.

ABOUT THE RESEARCHERS

Rainer Goebel
Professor for Cognitive Neuroscience
Maastricht University
r.goebel@maastrichtuniversity.nl

Leader of Human Brain Project Workpackage 3 – Adaptive networks for cognitive architectures: from advanced learning to neurorobotics and neuromorphic applications

Mario Senden
Assistant Professor
Maastricht University
Department of Cognitive Neuroscience
mario.senden@maastrichtuniversity.nl

Peter Zekert
EBRAINS AISBL
+49 2461 6196860
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Human Dexterity: A Proof of Concept


Source: EIN Presswire

Increasing Investments In Research Fuels Growth Of The Alpha Mannosidosis Market

Alpha Mannosidosis Market Report 2021: COVID-19 Growth And Change

Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, May 31, 2021 /EINPresswire.com/ — Increasing investments in research is expected to contribute to the growth of the alpha mannosidosis market in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for the rare genetic disease. However, several firms have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investment in research fuels the growth of the alpha mannosidosis market.

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.

Read More On The Global Alpha Mannosidosis Market Report:
https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market-report

The global alpha mannosidosis market size is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The alpha mannosidosis market is expected to reach $17.91 million in 2025 at a CAGR of 19.1%.

North America was the largest region in the alpha mannosidosis market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex.

The global alpha mannosidosis market research report is segmented –
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Specialty Clinics.

Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides alpha mannosidosis global market overview, forecast alpha mannosidosis global market size and growth for the whole market, alpha mannosidosis global market segments, and geographies, alpha mannosidosis global market trends, alpha mannosidosis global market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Alpha Mannosidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Transplant Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Cell and Gene Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-global-market-report-2020-30-covid-19-growth-and-change

Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

The Blood Group Typing Industry Grew With Increasing Number Of Blood Donations And Transfusions

Blood Group Typing Market Report 2021: COVID-19 Growth And Change

Blood Group Typing Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Blood Group Typing Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, May 31, 2021 /EINPresswire.com/ — Increasing number of blood donations and transfusions drove the blood group typing market during the historic period. Different non-profit organizations, government organizations and other agencies are emphasizing on the importance of blood donations and transfusions and spreading awareness through various campaigns. Increase in blood donations increased the demand for blood group typing so that the donor can know what type of blood they have. For instance, according to WHO, blood donations have increased from 2013 to 2018 with 7.8 million blood donations from voluntary unpaid donors being reported from 2013 to 2018. The increase in number of blood donations and transfusions, thereby contributed to growth of the blood typing market.

The blood group typing market consists of sale of blood group typing products and related services by entities (organizations, sole traders and partnerships) that provide blood group type details that are derived from certain tests. Blood group typing is a method that tells the type of blood a person has and it is done so that a person can safely donate blood or receive a blood transfusion.

Read More On The Global Blood Group Typing Market Report:
https://www.thebusinessresearchcompany.com/report/blood-group-typing-global-market-report

The global blood group typing market is expected to grow from $2.08 billion in 2020 to $2.34 billion in 2021 at a compound annual growth rate (CAGR) of 12.37%. The growth is mainly due to the rise in blood transfusions, crossmatch testing and prenatal testing, and technology advancements in blood testing reagents and instruments. The blood group typing market is expected to reach $3.59 billion in 2025 at a CAGR of 11.28%.

North America was the largest region in the blood group typing market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the blood group typing global market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Major players in the blood group typing industry are Grifols, Bio-Rad Laboratories, Immucor Inc., Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, AXO Science, Agena Bioscience, Merck KGaA, Beckman Coulter Inc, Sucuri Inc, Rapid Labs, AXO Science, Day Medical SA, and Novacyt Group.

The global blood group typing market is segmented by test type into antibody screening, cross-matching tests, ABO tests, antigen typing, HLA typing, by product into instruments, reagents and kits, by techniques into serology tests, molecular tests, and by end user into hospital based laboratories, independent laboratories and blood banks.

Blood Group Typing Global Market Report 2021: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides blood group typing global market overview, forecast blood group typing market size and growth for the whole market, blood group typing global market segments, and geographies, blood group typing market trends, blood group typing global market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Blood Group Typing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4092&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Patient Blood Management Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/patient-blood-management-market-global-report-2020-30-covid-19-growth-and-change

Blood Transfusion Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Blood Glucose Test Strips Market – By Technology (Glucose Oxidase And Glucose Dehydrogenase), By Type (Thick Film Electrochemical Films, Thin Film Electrochemical Films And Optical Strips), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/blood-glucose-test-strips-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Solid-state battery with 50% better environmental balance on short way to series production

Battery cell passes basic functionality tests. Production line of 200 MWh on the way to Gigafactory. Game changer and technology leader in battery industry.

TEUFEN / ST. GALLEN, APPENZELL AUSSERRHODEN, SCHWEIZ, May 31, 2021 /EINPresswire.com/ — An important milestone has been reached: The company High Performance Battery (HPB) has developed the world's first solid-state battery whose core – unlike all other solid-state battery projects – is the result of a chemical reaction within the battery. Whereas solid ion conductors are usually inserted into the battery as prefabricated parts, the HPB solid ion conductor is first created in the battery cell, similar to a "two-component glue". As a result, this technology elegantly solves significant hurdles for the series production of solid-state batteries as a possible successor technology to lithium-ion batteries.

The list of positive features of the HPB solid-state battery is long: The innovative battery technology of the High Performance Battery has an extremely long service life without loss of performance at almost constant capacity. Furthermore, the solid state battery is resistant to deep discharge and fast charging, the solid ion conductor is non-flammable and thus safe to use. In addition, the new technology has a 50 percent improved environmental balance compared to conventional lithium-ion batteries and does not require the controversial raw material cobalt. The innovative battery cell has already proven its basic functionality in initial tests.

Reliable storage technology for successful applications:

The new battery technology from High Performance Battery serves a broad field of applications: it has a high potential to be used in e-mobility – on land, on water and in the air – in the future. In particular, it is suitable for domestic energy supply and the intermediate storage of volatile electricity.
Market development is also unconventional: HBP grants licences to producers and users for attractive market segments. The production start of the first production line of 200 megawatt hours is planned for 2023. The modular structure of the production is intended to enable short-term entry and easy scaling to gigafactory level.

Environmentally friendly solid-state battery on the way to becoming a technology leader:

"The development of the solid-state battery is a great success for the energy industry and eMobility. The establishment of the first production offers the opportunity to position ourselves as a technology leader on the global market. In addition to selling the licences and preparing for the start of production, we are continuing to optimise the battery cell in terms of size and capacity," says Dr Thomas Lützenrath, COO of High Performance Battery.

High Performance Battery was founded in 2015 and is specialised in the research and development of high-tech rechargeable batteries with a unique combination of performance data: durable, non-flammable, deep discharge resistant, almost constant capacity with almost constant internal resistance, without raw material bottleneck, free of cobalt and with significantly better environmental effects than conventional lithium-ion batteries.

www.HighPerformanceBattery.ch/eng

Press contact:
HPB AG
Landhausstrasse 1
CH-9053 Teufen
Thomas Lützenrath
Info@HighPerformanceBattery.ch
+41768306645

Thomas Luetzenrath
High Performance Battery AG
info@highperformancebattery.ch


Source: EIN Presswire

Deep Pharma Intelligence Releases Analytical Report "Cell Therapies In Healthcare Landscape Overview 2021"

“Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts)”

“Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts)”

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, MedTech and Healthcare Tech industries”

— Deep Pharma Intelligence

LONDON, UNITED KINGDOM, May 31, 2021 /EINPresswire.com/ — Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is the first comprehensive and systematic overview of cell therapies landscape by the company. This report is specifically focused on Stem Cell therapies and Chimeric Antigen Receptor T-cell (CAR-T) therapies, and it is the first edition in a series of reports covering the landscape of cell therapies and related technologies and products.

The main aim of this report is to profile an ecosystem of biotech companies and technology developers, applying advanced biology techniques, experimentation tools, and advanced data analytics technologies for creating state-of-the-art stem cell-based products and therapies, and for creating robust clinically efficient and personalized CAR-T therapies — two exciting and rapidly evolving areas of modern biotech.

Link to the report "Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts)" – www.deep-pharma.tech/cell-therapies.

This report highlights 400 biotech companies and vendors, 200 biotech investors, and 15 pharma corporations active in the areas of stem cells research and CAR-T therapies, as well as selected R&D collaborations, funding rounds, research trends, industry trends, selected case studies, and other actionable insights about the industry.

With more than 100.000 research publications and above 1000 clinical trials taking place globally, the area of cell therapies research (stem cell and CAR-T) is steadily expanding in terms of new knowledge and understanding of fundamental biological processes associated with production and application of stem cells, CAR-T technologies, and other cell therapies in general. The area is characterized by a steady flow of scientific breakthroughs with high translational potential, which opens up a landscape of opportunities for prospective investors.

However, notwithstanding of substantial amount of clinical data showing relative safety and efficacy of cell therapies, related to stem cells and CAR-T, the overall presence of commercially available medical products and services is still rather limited, which is reflective of the fact that the market is in early days of development — with substantial growth potential overall.

Up to now, only 5 CAR-T therapies has been approved by FDA, including Abecma by Bluebird Bio and Bristol Myers Squibb, Tecartus™ by Kite Pharma, and others, as well as 19 Stem Cell products — all being blood-forming stem cells (also known as hematopoietic progenitor cells) that are derived from umbilical cord blood. These products are approved for use in patients with disorders that affect the production of blood.

The market of cell therapies is currently a growing opportunity for the private and institutional investors, and we expect the acceleration of funding inflow into the segments of stem cells and CAR-T technologies in the upcoming 2-5 years. Especially interesting opportunities emerge when companies develop specialized R&D platforms, capable of producing results with a wide variety of products and therapeutics areas.

About Deep Pharma Intelligence
Deep Pharma Intelligence is a joint venture of Deep Knowledge Analytics Pharma Division and BPT Analytics (BiopharmaTrend) producing powerful data mining and visualization systems, interactive analytics dashboards and industry reports offering deep technical insights, business intelligence, competitive analysis, industry benchmarking and strategic guidance in high growth and large opportunity areas of the pharma sector, including AI in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

About Deep Knowledge Analytics
Deep Knowledge Analytics is a DeepTech focused agency producing advanced analytics on DeepTech and frontier-technology industries using sophisticated multi-dimensional frameworks and algorithmic methods that combine hundreds of specially-designed and specifically-weighted metrics and parameters to deliver insightful market intelligence, pragmatic forecasting and tangible industry benchmarking.

About BPT Analytics (BiopharmaTrend)
BiopharmaTrend is a leading provider of analytics, market intelligence, articles, opinions, commentaries, and interviews on the pharmaceutical and healthcare industries. They are also currently developing an analytics platform that maps companies, competitors, key people, deals, venture rounds, news, trends, research articles, patents and other important data elements into industry knowledge graphs. The company was created to serve as a research engine for marketers, investors, business developers, innovation scouts, and all types of consultants looking for strategic and tactical insights into the pharma industry and healthcare.

About Deep Knowledge Group
Deep Knowledge Group is an international consortium of commercial and non-profit organizations focused on the synergetic convergence of DeepTech and Frontier Technologies (AI, Longevity, MedTech, FinTech, GovTech), applying progressive data-driven Invest-Tech solutions with a long-term strategic focus on AI in Healthcare, Longevity and Precision Health, and aiming to achieve positive impact through the support of progressive technologies for the benefit of humanity via scientific research, investment, entrepreneurship, analytics and philanthropy.

For press and media inquiries, please contact: info@deep-pharma.tech

Dr. Andrii Buvailo
Deep Pharma Intelligence
info@deep-pharma.tech


Source: EIN Presswire

PROGEAR Eyeguard Releases Scientific Proof that its Sports Safety Glasses Have the Fabrication Strength of Car Bumpers

Car manufacturers opt for high viscosity polycarbonate to increase the chance of the users’ survival during impact.

Car manufacturers opt for high viscosity polycarbonate to increase the chance of the users’ survival during impact.

The higher degree of entanglement means that in order to rupture, more polymer bonds need to be broken.At high impact, the external kinetic energy cancels out with this intermolecular force, and virtually “absorbs” the force that can hurt the person.

The higher degree of entanglement means that in order to rupture, more polymer bonds need to be broken.At high impact, the external kinetic energy cancels out with this intermolecular force, and virtually “absorbs” the force that can hurt the person.

Most people would think if a pair of tough designed glasses can withstand the weight of a car, it can surely protect your eyes. WRONG!

Most people would think if a pair of tough designed glasses can withstand the weight of a car, it can surely protect your eyes. WRONG!

Cutting-edge high-viscosity polycarbonate, recently discovered by scientists to be used in safety eyewear for unparalleled level of protection

PHOENIX , USA, May 31, 2021 /EINPresswire.com/ — E-Optician, the premier optical sports vision specialist and authorized reseller of PROGEAR® Eyeguard, today released information about the science behind its safety glasses. Scientists have proven that using high-viscosity polycarbonate, which is also used in car bumpers, absorbs impact to the eyes when athletes wear them. The glasses protect professional and amateur athletes alike from injury. This new discovery of adapting scientific materials for use in PROGEAR Eyeguard Sports Safety Glasses has made them the highest-rated safety eyewear product on the market today.

E-Optician is known for its selection of protective eyewear for athletes, as they are the leader in sports safety. Thanks to the discovery of high-viscosity polycarbonate used in protective eye gear, E-Optician is now offering its clients the most durable scientifically proven eyeglasses available.

“The sports eyewear scientists are pleased to announce that the same materials used in car bumpers were discovered to protect athletes competing in various sports. Surprisingly, the glasses can absorb a very strong impact experienced by players. Car manufacturers opt for this high-viscosity polycarbonate for car bumpers. The same materials in these car bumpers have now been incorporated into sports eyewear to lower the chance of serious injury. The bumpers increase driver and passenger survival during auto impact and we were able to adapt the high-viscosity polycarbonate into protective eyewear,” said PROGEAR spokesperson Judy Miller. “The specialized, scientifically proven material can absorb an incredible amount of force through its naturally strong molecular composition. The impact resistance is due to molecules that are ‘tangled’ and won’t rupture because they are thoroughly linked together. At high impact, the external kinetic energy ‘cancels’ out the strength of the tangled molecules, and virtually ‘absorbs’ the force that can cause injuries or fatalities. Our mission is to protect the person and for the glasses themselves to absorb the impact, to protect the wearer.”

Users of PROGEAR Eyeguard safety glasses are professional, collegiate and high school athletes. Athletes have much at stake when they play. In games, their eyesight must be close to perfect. When players need to wear regular glasses daily, they don’t want to risk dropping and breaking expensive eyewear while they play and are especially mindful of glass that can shatter upon impact from player-to-player impact or from falls.

Customers who visit the website can register to receive a limited-time free coupon for $80 off any Eyeguard purchase, including personalized prescription lenses, reducing the cost to as little as $99.

For more information or to make a purchase, visit e-optician.com/pages/eyeguard-technology-pr.

###

Media Relations
PR Services
email us here


Source: EIN Presswire